Alterity Therapeutics Ltd (ATHE) stock
ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
$1.86−0.09 (-4.85%)
Close on Nov 17, 2026Market cap $33.80MP/E –Yield –
Alterity Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was A$17.63M, up 22.4% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is A$18.64M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$17.63M | +22.4% |
| FY2025 | Jun 30, 2025 | A$14.40M | -22.7% |
| FY2024 | Jun 30, 2024 | A$18.64M | +41.3% |
| FY2023 | Jun 30, 2023 | A$13.20M | -10.5% |
| FY2022 | Jun 30, 2022 | A$14.75M | +20.0% |
| FY2021 | Jun 30, 2021 | A$12.28M | +21.6% |
| FY2020 | Jun 30, 2020 | A$10.10M | -22.2% |
| FY2019 | Jun 30, 2019 | A$12.98M | +93.8% |
| FY2018 | Jun 30, 2018 | A$6.70M | +17.5% |
| FY2017 | Jun 30, 2017 | A$5.70M | -40.5% |
| FY2016 | Jun 30, 2016 | A$9.59M | – |
See a number that looks wrong?